The survival rate for thousands of men with aggressive prostate cancer could improve by using abiraterone, which may “reduce the overall burden for both patients and health services,” said Professor Gerhardt Attard (UCL Cancer Institute).
Read: Times (£), More: Mail Online, UCL News
Close
